Patents by Inventor Stephanie Kade

Stephanie Kade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis of a neuroautoimmune disease
    Patent number: 11371991
    Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: June 28, 2022
    Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Winfried Stoecker, Lars Komorowski, Ramona Miske, Yvonne Denno, Madeleine Scharf, Christian Probst, Iswariya Venkataraman, Stephanie Kade
  • DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE
    Publication number: 20200309775
    Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Winfried STOECKER, Lars KOMOROWSKI, Ramona MISKE, Yvonne DENNO, Madeleine SCHARF, Christian PROBST, Iswariya VENKATARAMAN, Stephanie KADE
  • Diagnosis of a neuroautoimmune disease
    Patent number: 10725035
    Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 28, 2020
    Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Winfried Stoecker, Lars Komorowski, Ramona Miske, Yvonne Denno, Madeleine Scharf, Christian Probst, Iswariya Venkataraman, Stephanie Kade
  • DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE
    Publication number: 20180364228
    Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Winfried STOECKER, Lars KOMOROWSKI, Ramona MISKE, Yvonne DENNO, Madeleine SCHARF, Christian PROBST, Iswariya VENKATARAMAN, Stephanie KADE
  • Diagnosis of a neuroautoimmune disease comprising measuring autoantibodies to flotillin1 and/or flotillin2
    Patent number: 10138285
    Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 27, 2018
    Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Winfried Stoecker, Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Stefanie Hahn, Stephanie Kade, George Trendelenburg
  • DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE
    Publication number: 20160355565
    Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Winfried STOECKER, Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Stefanie Hahn, Stephanie Kade, George Trendelenburg